In addition to EGFR, antibodies targeting angiogenesis have also been approved for treatment, such as bevacizumab and ramucirumab, which inhibit VEGF and VEGFR-2, respectively, significantly delaying tumor progression. The gene discussed is EGFR; the disease is neoplasm.